A cross-border Willkie team advises Sebia on the contemplated acquisition of ORGENTEC Diagnostika, a world market leader in the diagnostic industry. On June 30, Willkie advised Sebia on its announced acquisition of specialty diagnostic leader ORGENTEC Diagnostika from Water Street Healthcare Partners. The state-of-the-art diagnostic company will provide development opportunities and expand Sebia’s capabilities in autoimmunity, infectious diseases, and clinical trials. Based in Mainz, Germany, ORGENTEC Diagnostika is a world market leader in the development, production, and marketing of diagnostic tests to detect autoimmune and blood diagnostics and treatment-associated monitoring. Clinical areas include: inflammatory rheumatic diseases, thrombosis diagnostics, blood diagnostics for the serological detection of autoimmune vasculitis, thyroid diagnostics, gastroenterology and diabetes diagnostics. Founded in 1967, Sebia is a world leading provider of clinical protein electrophoresis equipment and reagents, a technology used for in-vitro diagnostic testing. Its systems analyze proteins in order to screen and monitor various diseases and conditions; primarily oncology (multiple myeloma), metabolic disorders such as diabetes and also hemoglobinopathy and rare pathologies. The company is headquartered in Lisses, France, and operates across more than 120 countries. Sebia is owned by CVC Capital Partners, Téthys Invest and Caisse de dépôt et placement du Québec. Willkie deal team was led in Frankfurt by partners Georg Linde and Matthias Schudlo and included Counsel Michael Ilter; in Paris by partners Cédric Hajage and Grégoire Finance and in London by partner Sebastian Fitzgerald.